US FDA halts RegeneRx's heart drug program over manufacturing concerns
This article was originally published in Scrip
Executive Summary
The US FDA placed a clinical hold on RegeneRx Biopharmaceuticals Phase II trial of RGN-352, an injectable formulation of Thymosin beta-4, because of manufacturing concerns.